51 results on '"Pappa, Vasiliki"'
Search Results
2. Lipid metabolites of the phospholipase A2 pathway and inflammatory cytokines are associated with brain volume in paediatric cerebral malaria.
- Author
-
Pappa, Vasiliki, Seydel, Karl, Gupta, Sanchit, Feintuch, Catherine M., Potchen, Michael J., Kampondeni, Samuel, Goldman-Yassen, Adam, Veenstra, Mike, Lopez, Lillie, Kim, Ryung S., Berman, Joan W., Taylor, Terrie, and Daily, Johanna P.
- Subjects
- *
CEREBRAL malaria , *METABOLITES , *CYTOKINES , *BRAIN injuries , *THERAPEUTICS - Abstract
Background: Cerebral malaria (CM) remains a significant cause of morbidity and mortality in children in sub-Saharan Africa. CM mortality has been associated with increased brain volume, seen on neuroimaging studies. Methods: To examine the potential role of blood metabolites and inflammatory mediators in increased brain volume in Malawian children with CM, an association study was performed between plasma metabolites, cytokine levels and phospholipase A2 (PLA2) activity with brain volume. Results: The metabolomics analysis demonstrated arachidonic acid and other lysophospholipids to be positively associated with brain swelling. These lipids are products of the PLA2 enzyme and an association of plasma PLA2 enzymatic activity with brain swelling was confirmed. TNFα, which can upregulate PLA2 activity, was associated with brain volume. In addition, CCL2 and IL-8 were also associated with brain volume. Some of these cytokines can alter endothelial cell tight junction proteins and increase blood brain barrier permeability. Conclusions: Taken together, paediatric CM brain volume was associated with products of the PLA2 pathway and inflammatory cytokines. Their role in causality is unknown. These molecules will need to undergo testing in vitro and in animal models to understand their role in processes of increased brain volume. These observations provide novel data on host physiology associated with paediatric CM brain swelling, and may both inform pathogenesis models and suggest adjunct therapies that could improve the morbidity and mortality associated with paediatric CM. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
3. Novel constitutional translocations t(3;5)(p25;q22) and t(1;14)(p31;q21) in patients with acute leukemia.
- Author
-
Panani, Anna D., Pappa, Vasiliki, and Raptis, Sotirios A.
- Subjects
- *
PATIENTS , *LEUKEMIA , *RISK , *DISEASES - Abstract
Certain constitutional translocations have been described to be associated with an increased risk of malignant diseases. We report here two patients, one with acute myeloid leukemia (AML) and another with biphenotypic acute leukemia, in whom constitutional translocations t(3;5)(p25;q22) and t(1;14)(p31;q21) were observed, respectively. To our knowledge, none of the above translocations has been previously reported. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
4. Neurokinin-1 receptor signaling induces a pro-inflammatory transcriptomic profile in CD16+ monocytes.
- Author
-
Pappa, Vasiliki, Spitsin, Sergei, Gaskill, Peter J., and Douglas, Steven D.
- Subjects
- *
MONOCYTES , *RNA sequencing , *GENES , *CELL adhesion , *GENE expression - Abstract
Neurokinin-1 receptor (NK1R) signaling can be immunomodulatory and it can lead to preferential transmigration of CD14+CD16+ monocytes across the blood brain barrier, potentially promoting the development of inflammatory neurological diseases, such as neuroHIV. To evaluate how NK1R signaling alters monocyte biology, RNA sequencing was used to define NK1R-mediated transcriptional changes in different monocyte subsets. The data show that NK1R activation induces a greater number of changes in CD14+CD16+ monocytes (152 differentially expressed genes), than in CD14+CD16− monocytes (36 genes), including increases in the expression of NF-κB and components of the NLRP3 inflammasome pathway. These results suggest that NK1R may alter the inflammatory state of CD14+CD16+ monocytes, influencing the development of neuroinflammation. [Display omitted] • Neurokinin-1 receptor signaling impacts gene expression mostly in CD16+ monocytes. • Neurokinin-1 receptor signaling upregulates pro-inflammatory transcripts and NLRP3. • Neurokinin-1 receptor signaling upregulates cell adhesion transcripts. • Neurokinin-1 receptor signaling is involved in negative regulation of apoptosis. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Deletion (11)(q13) as the sole anomaly in myeloid malignancies: four new cases and a short review.
- Author
-
Panani, Anna D., Pappa, Vasiliki, Papageorgiou, Sotirios, Stamatelli, Francs, and Raptis, Sotirios A.
- Subjects
- *
CHROMOSOMES , *HEMATOLOGY , *MYELODYSPLASTIC syndromes , *PATIENTS - Abstract
Chromosomal abnormalities are of significance in the study of hematologic malignancies. We describe one case of myelodysplastic syndrome (MDS) diagnosed 22 years ago as polycythemia vera (PV) as well as a case of unclassified myeloproliferative disease (MPD) with a poor clinical course. Both patients presented del(11)(q13) as the sole clonal abnormality. This abnormality was also found in two additional cases of MDS. Summarizing the literature, only ten other cases of myeloid malignancies with deletion of 11q involving band q13 as the sole anomaly have been reported. All but one of these cases presented interstitial deletions. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
6. The effect of 5‐azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes.
- Author
-
Diamantopoulos, Panagiotis T., Symeonidis, Argiris, Pappa, Vasiliki, Kotsianidis, Ioannis, Galanopoulos, Athanasios, Pontikoglou, Charalampos, Anagnostopoulos, Achilles, Vassilopoulos, George, Zikos, Panagiotis, Hatzimichael, Eleftheria, Papaioannou, Maria, Megalakaki, Aekaterini, Repousis, Panagiotis, Kotsopoulou, Maria, Dimou, Maria, Solomou, Elena, Dryllis, Georgios, Tsokanas, Dimitrios, Papoutselis, Menelaos‐Konstantinos, and Papageorgiou, Sotirios
- Subjects
- *
MYELODYSPLASTIC syndromes , *TREATMENT delay (Medicine) , *PROGNOSIS , *ACUTE myeloid leukemia , *TREATMENT effectiveness - Abstract
Summary: The regimen of 5‐azacytidine for patients with myelodysplastic syndrome (MDS) has remained unchanged since its first approval. Although several modifications have since been made and delays and dose reductions are common especially during the first treatment cycles, there are minimal data on the prognostic effect of these modifications. In this study, based on data from 897 patients with MDS treated with 5‐azacytidine recorded in a national registry, the effect of treatment delays and dose reductions on response, transformation to acute myeloid leukaemia, and survival (after 5‐azacytidine initiation, OST) were analysed. Delays during the first two cycles were noted in 150 patients (16·7%) and were found to adversely affect OST independently of the International Prognostic Scoring System score [hazard ratio (HR), 1·368; P = 0·033] or pre‐existing neutropenia (HR, 1·42; P = 0·015). In patients achieving a response, delays before response achievement were correlated with its type (complete remission, 2·8 days/cycle; partial remission, 3·3 days/cycle; haematologic improvement, 5·6 days/cycle; P = 0·041), while delays after response achievement did not have any effect on retention of response or survival. Dose reductions were found to have no prognostic impact. Based on our results, treatment delays especially during the first cycles should be avoided, even in neutropenic patients. This strict strategy may be loosened after achieving a favourable response. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Real-Life Multicenter Experience of Venetoclax in Combination with Hypomethylating Agents in Previously Untreated Adult Patients with Acute Myeloid Leukemia in Greece.
- Author
-
Chatzilygeroudi, Theodora, Darmani, Ismini, El Gkotmi, Natali, Vryttia, Pinelopi, Douna, Stavroula, Bouchla, Anthi, Labropoulou, Vasiliki, Kotsopoulou, Maria, Symeonidis, Argiris, Pagoni, Maria, Pappa, Vasiliki, and Papageorgiou, Sotirios G.
- Subjects
- *
ACUTE myeloid leukemia , *VENETOCLAX , *MYCOSES , *ADULTS , *SURVIVAL rate - Abstract
Background: The landscape of first-line treatment for acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy has changed remarkably after venetoclax approval. Accumulating real-world data further apprises us with more knowledgeable use. To assess the efficacy and safety challenges in the real-life setting of the combination of hypomethylated agent (HMA) and venetoclax, we conducted a multi-center retrospective study. Methods: Forty adult AML patients treated with the combination of HMA and venetoclax as a first-line treatment after full approval (2020) were included. To confirm VIALE-A results, this group was compared to a historical cohort of 17 chemotherapy-ineligible AML patients treated with HMA monotherapy before 2020. Results: The combination of HMA-venetoclax achieved a composite complete response rate of 86.8% (p < 0.001), median overall survival, and event-free survival of 33.8 and 19.7 months, respectively, in a median follow-up of 17.8 months (pos < 0.001, HR = 0.276, CI: 0.132–0.575, pEFS = 0.004, HR = 0.367, CI: 0.174–0.773). High rates of neutropenia (90%) and consequent infection rates (57.5%) were noted. Only 55% of our patients received antifungal prophylaxis, as its use remains controversial, and invasive fungal infections were presented in 7.5%. Conclusions: Evidently, venetoclax-HMA yields high response rates and profound survival benefits in real life and has changed our approach to alternative chemotherapy options. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Primary Adrenal Lymphomas with Cushing's Syndrome: Two Cases with Evidence of Endogeneous Cortisol Production by the Neoplastic Lymphoid Cells.
- Author
-
Papageorgiou, Sotirios G., Mavroeidi, Ioanna, Kostakis, Marios, Spathis, Aris, Leventakou, Danai, Kritikou, Evangelia, Oikonomopoulos, Nikolaos, Kourkouti, Chrysoula, Krania, Maria, Bouchla, Anthi, Thomopoulos, Thomas, Tsakiraki, Zoi, Markakis, Konstantinos, Panayiotides, Ioannis G., Thomaidis, Nikolaos, Pappa, Vasiliki, Foukas, Periklis G., and Peppa, Melpomeni
- Subjects
- *
CUSHING'S syndrome , *ADRENAL insufficiency , *DIFFUSE large B-cell lymphomas , *LUMBAR pain , *HYDROCORTISONE , *LYMPHOMAS - Abstract
Primary adrenal lymphoma (PAL) is a rare entity that presents as unilateral or bilateral rapidly growing adrenal masses, with signs and symptoms most commonly related to adrenal insufficiency due to the mass effect on the surrounding tissues. Although steroeidogenesis has not been previously described in PAL, we herein report two cases of PAL presenting as adrenal incidentalomas (AIs) that demonstrated autonomous cortisol production. A 52-year-old woman presented with lumbar pain; a computed tomography (CT) scan demonstrated a left AI measuring 8.5 × 15 × 10 cm. Similarly, an 80-year-old woman presented with lumbar pain, demonstrating in a CT scan a bilateral AI (right: 9 × 6.5 cm, left: 3.6 × 3.2 cm). Both cases underwent a full hormonal evaluation according to the algorithm for the investigation of AIs, demonstrating increased 24-h cortisol excretion, suppressed fasting adrenocorticotropic hormone (ACTH) levels, and non-suppressed serum cortisol levels in both the overnight and the low-dose dexamethasone suppression tests, indicating autonomous cortisol secretion and Cushing's syndrome. In a relatively short time, both patients developed night sweats, and their clinical picture deteriorated, while the CT scans showed increased dimensions of the masses with radiological characteristics compatible to lymphoma. Both patients underwent ultrasound-guided biopsies (FNBs), revealing infiltration of the left adrenal by diffuse large B-cell lymphoma in the first case, whereas bilateral adrenal infiltration from the same histological type was noted in the second case. Subsequently, they were treated with immunochemotherapy, but the second patient died from an infection shortly after the initiation of the treatment. To our knowledge, this is the first report of PAL presenting with Cushing's syndrome due to autonomous cortisol production, indicating that neoplastic lymphoid cells in PAL might acquire the potential for steroidogenesis; therefore, more cases of PAL should be analyzed so as to further elucidate the complex pathogenesis and the natural course of this entity. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Azacitidine in a patient with newly diagnosed acute myeloid leukemia and poor risk cytogenetics: Outcomes of prolonged therapy
- Author
-
Pappa, Vasiliki, Girkas, Konstantinos, Sambani, Constantina, Pagageorgiou, Sotiris, Tsirigiotis, Panagiotis, Karvounis, Kiki, Stathopoulou, Evangelia, Economopoulos, Theofanis, Dimitriadis, George, and Dervenoulas, Ioannis
- Published
- 2012
- Full Text
- View/download PDF
10. Dasatinib induces long-term remission in imatinib-resistant Philadelphia chromosome-positive acute megakaryoblastic leukemia but fails to prevent development of central nervous system progression
- Author
-
Papageorgiou, Sotirios G., Pappa, Vasiliki, Economopoulou, Christina, Tsirigotis, Panagiotis, Konsioti, Frida, Ionnidou, Eleni-Dikaia, Chondropoulos, Spyros, Vasilatou, Diamantina, Papageorgiou, Efstathios, Economopoulos, Theofanis, and Dervenoulas, John
- Published
- 2010
- Full Text
- View/download PDF
11. Breakthrough Acute Necrotizing Invasive Fungal Rhinosinusitis by Alternaria alternata in a Patient with Acute Lymphoblastic Leukemia on Anidulafungin Therapy and Case-Based Literature Review.
- Author
-
Tyrellis, Giorgos, Siopi, Maria, Leventakou, Danai, Delides, Alexander, Maragkoudakis, Pavlos, Korres, George, Apostolopoulou, Christina, Gouloumi, Alina-Roxani, Pappa, Vasiliki, Pournaras, Spyros, Panayiotides, Ioannis, and Meletiadis, Joseph
- Subjects
- *
ALTERNARIA alternata , *LYMPHOBLASTIC leukemia , *ACUTE leukemia , *SINUSITIS , *BLOOD diseases , *MYCOSES - Abstract
Alternaria spp. have emerged as opportunistic pathogens particularly in immunosuppressed patients. A case of a breakthrough acute invasive fungal rhinosinusitis (AIFRS), caused by Alternaria alternata, is reported in a patient with acute lymphoblastic leukemia (ALL) on anidulafungin therapy, who was successfully treated with liposomal amphotericin B and surgical intervention. To date, 20 cases of AIFRS due to Alternaria spp. have been described, 19 in the USA and 1 in Chile, making this case report the first case of AIFRS due to Alternaria in Europe. The patients had median (range) age 25 (2–56) years (65% female), almost all of them (19/20) with hematological diseases and severe neutropenia (8–41 days pre-infection). Amphotericin B was the most frequently used antifungal agent, either alone or in combination. In all of the cases, systemic antifungal therapy was combined with surgery. Despite stabilization or improvement of the AIFRS, mortality was 38% (5 days to 8 months post-surgical debridement) due to their underlying disease or other infections without sign of AIFRS at autopsy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Silencing of the DNA damage repair regulator <italic>PPP1R15A</italic> sensitizes acute myeloid leukemia cells to chemotherapy.
- Author
-
Bouchla, Anthi, Sotiropoulou, Christina D., Esteb, Christopher, Loupis, Theodoros, Papageorgiou, Sotirios G., Deliconstantinos, Georgia G., Pagoni, Maria, Hatzimichael, Eleftheria, Dellatola, Maria, Kalomoiri, Smaragdi, Apostolidou, Elisavet, Kontos, Christos K., Thomopoulos, Thomas P., Karantanos, Theodoros, and Pappa, Vasiliki
- Abstract
Acute Myeloid Leukemia (AML) is a life-threatening disease whose induction treatment consists of combination chemotherapy with Idarubicin and Cytarabine for fit patients. Treatment failures are frequent, urging the need for novel treatments for this disease. The DNA Damage Response Mechanism (DDR) comprises numerous molecules and pathways intended to arrest the cell cycle until DNA damage is repaired or else drive the cell to apoptosis. AML-derived cell lines after treatment with Idarubicin and Cytarabine were used for studying the expression profile of 84 DDR genes, through PCR arrays. Utilizing de novo AML patient and control samples we studied the expression of
PPP1R15A, CDKN1A, GADD45A, GADD45G , andEXO1. Next, we performedPPP1R15A silencing in AML cell lines in two separate experiments using siRNA and CRISPR-cas9, respectively. Our findings highlight that DDR regulators demonstrate increased expression in patients with high cytogenetic risk possibly reflecting increased genotoxic stress. Especially,PPP1R15A is mainly involved in the recovery of the cells from stress and it was the only DDR gene upregulated in AML patients. ThePPP1R15A silencing resulted in decreased viability of Idarubicin and Cytarabine-treated cell lines, in contrast to untreated cells. These findings shed light on new strategies to enhance chemotherapy efficacy and demonstrate thatPPP1R15A is an important DDR regulator in AML and its downregulation might be a safe and effective way to increase sensitivity to chemotherapy in this disease. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
13. Characterizing Kinetics and Avidity of SARS-CoV-2 Antibody Responses in COVID-19 Greek Patients.
- Author
-
Labropoulou, Stavroula, Vassilaki, Niki, Milona, Raphaela S., Terpos, Evangelos, Politou, Marianna, Pappa, Vasiliki, Pagoni, Maria, Grouzi, Elisavet, Dimopoulos, Meletios A., Mentis, Andreas, Emmanouil, Mary, and Angelakis, Emmanouil
- Subjects
- *
COVID-19 , *ANTIBODY formation , *SARS-CoV-2 , *HERD immunity , *IMMUNE response - Abstract
In-depth understanding of the immune response provoked by SARS-CoV-2 infection is necessary, as there is a great risk of reinfection and a difficulty in achieving herd immunity due to a decline in both antibody concentration and avidity. Avidity testing, however, could overcome variability in the immune response associated with sex or clinical symptoms, and thus differentiate between recent and past infections. In this context, here, we analyzed SARS-CoV-2 antibody kinetics and avidity in Greek hospitalized (26%) and non-hospitalized (74%) COVID-19 patients (N = 71) in the course of up to 15 months after their infection to improve the accuracy of the serological diagnosis in dating the onset of the infection. The results showed that IgG-S1 levels decline significantly at four months (p = 0.0239) in both groups of patients and are higher in hospitalized ones (up to 2.1-fold, p < 0.001). Additionally, hospitalized patients' titers drop greatly and are equalized to non-hospitalized ones only at a time-point of twelve to fifteen months. Antibody levels of women in total remain more stable months after infection, compared to men. Furthermore, we examined the differential maturation of IgG avidity after SARS-CoV-2 infection, showing an incomplete maturation of avidity that results in a plateau at four months after infection. We also defined 38.2% avidity (sensitivity: 58.9%, specificity: 90.91%) as an appropriate "cut-off" that could be used to determine the stage of infection before avidity reaches a plateau. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-Azacytidine.
- Author
-
Kontandreopoulou, Christina-Nefeli, Diamantopoulos, Panagiotis T., Giannopoulos, Andreas, Symeonidis, Argiris, Kotsianidis, Ioannis, Pappa, Vasiliki, Galanopoulos, Athanasios, Panayiotidis, Panayiotis, Dimou, Maria, Solomou, Elena, Loupis, Theodoros, Zoi, Katerina, Giannakopoulou, Nefeli, Dryllis, Georgios, Hatzidavid, Sevastianos, and Viniou, Nora-Athina
- Subjects
- *
RIBONUCLEOSIDE diphosphate reductase , *MYELODYSPLASTIC syndromes , *PROGNOSIS , *AZACITIDINE , *BONE marrow - Abstract
Ribonucleotide Reductase (RNR) is a two-subunit (RRM1, RRM2) enzyme, responsible for the conversion of ribonucleotides to deoxyribonucleotides required for DNA replication. To evaluate RNR as a biomarker of response to 5-azacytidine, we measured RNR mRNA levels by a quantitative real-time PCR in bone marrow samples of 98 patients with myelodysplastic syndrome (MDS) treated with 5-azacytidine with parallel quantification of the gene promoter's methylation. Patients with low RRM1 levels had a high RRM1 methylation status (p = 0.005) and a better response to treatment with 5-azacytidine (p = 0.019). A next-generation sequencing for genes of interest in MDS was also carried out in a subset of 61 samples. Splicing factor mutations were correlated with lower RRM1 mRNA levels (p = 0.044). Our results suggest that the expression of RNR is correlated with clinical outcomes, thus its expression could be used as a prognostic factor for response to 5-azacytidine and a possible therapeutic target in MDS. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Epigenetics in Gastrointestinal Stromal Tumors: Clinical Implications and Potential Therapeutic Perspectives.
- Author
-
Sioulas, Athanasios, Vasilatou, Diamantina, Pappa, Vasiliki, Dimitriadis, George, and Triantafyllou, Konstantinos
- Subjects
- *
GASTROINTESTINAL stromal tumors , *EPIGENETICS , *THERAPEUTICS , *MICRORNA , *DNA methylation , *HISTONES , *CHROMATIN , *TUMOR treatment - Abstract
Gastrointestinal stromal tumors (GIST) represent the most common mesenchymal neoplasms affecting the gastrointestinal tract. Activating mutations in either the KIT or PDGFRa gene are the principal oncogenic triggers with the former accounting for more than 80 % of cases. In the small subset of GIST that are wild type for both the aforementioned changes, other germline or somatic mutations have been identified. GIST exhibit a highly variable clinical behavior and the main prognostic determinants are tumor size, mitotic rate, and location. It is, however, strongly believed that, beyond classic genetics, additional epigenetic phenomena such as DNA hypomethylation and hypermethylation, microRNA alterations, and chromatin modifications underlie GIST tumorigenesis and influence the clinical course and response to standard treatment. This review aims to illuminate current advances in terms of epigenetics in GIST, as well as possible implications in prognosis and therapeutics. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
16. A 3′ tRNA‐derived fragment produced by tRNALeuAAG and tRNALeuTAG is associated with poor prognosis in B‐cell chronic lymphocytic leukemia, independently of classical prognostic factors.
- Author
-
Katsaraki, Katerina, Adamopoulos, Panagiotis G., Papageorgiou, Sotirios G., Pappa, Vasiliki, Scorilas, Andreas, and Kontos, Christos K.
- Subjects
- *
CHRONIC lymphocytic leukemia , *PROGNOSIS , *CHRONIC leukemia - Abstract
Objective: 3′ tRNA‐derived fragments (3′ tRFs) are important epigenetic regulators in normal and pathological conditions. In this study, we aimed to explore the potential value of a 3′ tRF as a prognostic and/or screening biomarker for B‐cell chronic lymphocytic leukemia (B‐CLL). Methods: Publicly available next‐generation sequencing data from 20 B‐CLL cases were analyzed, followed by prediction of targets of the most abundantly and ubiquitously expressed 3′ tRFs, leading to selection of tRF‐LeuAAG/TAG. PBMCs were isolated from blood samples of 91 B‐CLL patients and 43 non‐leukemic donors, followed by total RNA extraction, in‐vitro polyadenylation, and first‐strand cDNA synthesis. Next, a real‐time quantitative PCR (qPCR) assay was developed for the accurate quantification of tRF‐LeuAAG/TAG and applied in all samples, prior to biostatistical analysis. Results: High tRF‐LeuAAG/TAG levels are associated with inferior overall survival (OS) of B‐CLL patients. The unfavorable significance of tRF‐LeuAAG/TAG was independent of established prognostic factors in B‐CLL. Stratified Kaplan‐Meier OS analysis uncovered the unfavorable prognostic role of high tRF‐LeuAAG/TAG levels for patients in Binet A or Rai I stage, negative CD38 expression, mutated, or unmutated IGHV genomic locus. Conclusion: Our approach revealed the independent prognostic value of a particular 3′ tRF, derived from tRNALeuAAG and tRNALeuTAG (tRF‐LeuAAG/TAG) in B‐CLL. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma.
- Author
-
Karagianni, Fani, Piperi, Christina, Mpakou, Vassiliki, Spathis, Aris, Foukas, Periklis G., Dalamaga, Maria, Pappa, Vasiliki, and Papadavid, Evangelia
- Subjects
- *
CUTANEOUS T-cell lymphoma , *MYCOSIS fungoides , *HISTONE deacetylase inhibitors , *LEUKAPHERESIS , *CELL lines , *CELL proliferation - Abstract
Background: The combination of JAK/STAT and HDAC inhibitors exerted beneficial effects in haematological malignancies, presenting promising therapeutic CTCL targets. We aim to investigate the efficacy of JAK1/2i ruxolitinib in combination with HDACi resminostat in CTCL in vitro. Material & methods: Non-toxic concentrations of ruxolitinib and/or resminostat were administered to MyLa (MF) and SeAx (SS) cells for 24h. Cytotoxicity, cell proliferation and apoptosis were estimated through MTT, BrdU/7AAD and Annexin V/PI assay. Multi-pathway analysis was performed to investigate the effect of JAK1/2i and/or HDACi on JAK/STAT, Akt/mTOR and MAPK signalling pathways. Results: Both drugs and their combination were cytotoxic in MyLa (p<0.05) and in SeAx cell line (p<0.001), inhibited proliferation of MyLa (p<0.001) and SeAx (p<0.001) at 24h, compared to untreated cells. Moreover, combined drug treatment induced apoptosis after 24h (p<0.001) in MyLa, and SeAx (p<0.001). The combination of drugs had a strong synergistic effect with a CI<1. Importantly, the drugs' combination inhibited phosphorylation of STAT3 (p<0.001), Akt (p<0.05), ERK1/2 (p<0.001) and JNK (p<0.001) in MyLa, while it reduced activation of Akt (p<0.05) and JNK (p<0.001) in SeAx. Conclusion: The JAKi/HDACi combination exhibited substantial anti-tumor effects in CTCL cell lines, and may represent a promising novel therapeutic modality for CTCL patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
18. Superiority of synovial membrane mesenchymal stem cells in chondrogenesis, osteogenesis, myogenesis and tenogenesis in a rabbit model.
- Author
-
Bami, Myrto, Sarlikiotis, Thomas, Milonaki, Mandy, Vikentiou, Myrofora, Konsta, Evgenia, Kapsimali, Violetta, Pappa, Vasiliki, Koulalis, Dimitrios, Johnson, Elizabeth O, and Soucacos, Panayotis N
- Subjects
- *
SYNOVIAL membranes , *MESENCHYMAL stem cells , *BONE growth , *CHONDROGENESIS , *MYOGENESIS , *ADIPOSE tissue transplantation , *ROTATOR cuff , *CELL differentiation , *RABBITS , *MUSCULOSKELETAL system , *ANIMALS - Abstract
Engineering complex tissues is perhaps the most ambitious goal of all tissue engineers. Despite significant advances in tissue engineering, which have resulted in successful engineering of simple tissues such as skin and cartilage, there are a number of challenges that remain in engineering of complex, hybrid tissue structures, such as osteochondral tissue. Mesenchymal stem cells (MSCs) have the capacity to highly proliferate in an undifferentiated state and the potential to differentiate into a variety of different lineages, providing a promising single cell source to produce multiple cell types. MSC obtained from adult human contribute to the regeneration of mesenchymal tissues such as bone, cartilage, fat, muscle, tendon and marrow stroma. In the present study, the regeneration capacity of multipotent MSCs derived from different tissues in the rabbit were compared. Specifically the aim of this study was to isolate and characterize rabbit adult stem cell populations from bone marrow, adipose, synovial membrane, rotator cuff, ligament and tendon and assess their cell morphology, growth rate, cell surface markers and differentiation capacity. MSCs derived from synovial membrane showed superiority in terms of chondrogenesis, osteogenesis, myogenesis and tenogenesis, suggesting that synovial membrane-derived MSCs would be a good candidate for efforts to regenerate musculoskeletal tissues. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
19. A novel, mitochondrial, internal tRNA-derived RNA fragment possesses clinical utility as a molecular prognostic biomarker in chronic lymphocytic leukemia.
- Author
-
Karousi, Paraskevi, Adamopoulos, Panagiotis G., Papageorgiou, Sotirios G., Pappa, Vasiliki, Scorilas, Andreas, and Kontos, Christos K.
- Subjects
- *
CHRONIC lymphocytic leukemia , *TRANSFER RNA , *BIOMARKERS , *IMMUNOGLOBULIN heavy chains , *MANN Whitney U Test , *NON-coding RNA - Abstract
• A qPCR assay was developed for the quantification of a new mt-tRNA-derived fragment. • i-tRF-PheGAA can distinguish between CLL patients and normal controls. • An association was observed between i-tRF-PheGAA expression and CLL clinical stage. • Patients overexpressing i-tRF-PheGAA show significantly poorer overall survival. • The prognostic power of i-tRF-PheGAA is independent of established prognosticators. Chronic lymphocytic leukemia (CLL) is the most common leukemia among adults. The prognosis of CLL patients varies considerably. Transfer RNA-derived RNA fragments (tRFs) constitute a class of small non-coding RNA fragments excised from mature tRNAs and pre-tRNAs located in nuclei as well as in mitochondria. In this study, the clinical utility of i-tRF-PheGAA, a novel mitochondrial tRF, was investigated in CLL. Peripheral blood mononuclear cells (PBMCs) were isolated from 91 CLL patients and 43 non-leukemic controls. Total RNA was isolated from each sample, polyadenylated at the 3′ end and reversely transcribed. An in-house developed real-time quantitative PCR assay was developed and applied, and the results were biostatistically analyzed. For the normalization of the i-tRF-PheGAA expression levels, the expression of a small nucleolar RNA (RNU48) was used as reference. Mann-Whitney U test showed that i-tRF-PheGAA can distinguish between CLL samples and normal controls (p < 0.001). As determined by Kaplan-Meier survival analysis, overexpression of i-tRF-PheGAA was related to poor overall survival of the CLL patients (p < 0.001). Univariate bootstrap Cox regression analysis exhibited a higher hazard ratio of 7.95 (95% CI = 2.37–26.72, p < 0.001) for patients with positive i-tRF-PheGAA expression status. Multivariate bootstrap Cox regression analysis showed that the prognostic value of this tRF is independent of clinical stage, mutational status of the immunoglobulin heavy chain variable (IGHV) genetic locus, and CD38 expression status (p = 0.010). Our results show that i-tRF-PheGAA can serve as a molecular biomarker of poor prognosis in CLL, alongside with the existing factors for CLL prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
20. Erdheim–Chester Disease and Acute Myeloid Leukemia with Mutated NPM1 in a Patient with Clonal Hematopoiesis: A Case Report.
- Author
-
Papageorgiou, Sotirios G, Divane, Aspasia, Roumelioti, Maria, Kottaridi, Christine, Bouchla, Anthi, Georgakopoulos, Alexandros, Ieremiadou, Fotini, Daraki, Aggeliki, Bazani, Efthymia, Thomopoulos, Thomas P, Chatziioannou, Sofia, Mavrogenis, Andreas, Panayiotidis, Panayiotis, Panayiotides, Ioannis G, Pappa, Vasiliki, and Foukas, Periklis G
- Subjects
- *
ACUTE myeloid leukemia , *HEMATOPOIESIS , *KARYOTYPES , *NUCLEOTIDE sequencing - Abstract
Background: Erdheim–Chester Disease (ECD) is a clonal non-Langerhans histiocytosis, classified as a macrophage-dendritic cell neoplasm in the 2016 WHO classification. The exact cell of origin of ECD is unknown, although some limited evidence suggests that it arises from myeloid progenitors. Case Presentation: A 43-year-old patient, diagnosed with BRAFV600E mutated ECD, developed NPM1+/FLT3+ acute myeloid leukemia (AML) with wild-type BRAF, 15 months after the initial ECD diagnosis. The patient received intensive chemotherapy plus midostaurin, followed by midostaurin maintenance. Six months into maintenance, the patient remains in complete remission with low-level measurable residual disease, whereas ECD shows a sustained partial metabolic response. Molecular karyotype at several distinct timepoints, namely ECD diagnosis, AML diagnosis, and following treatment of AML, highlighted a molecular signature, indicative of a persistent, underlying clonal hematopoiesis. Conclusion: This case report suggests that ECD and AML might represent an expansion of two distinct clones in a background of clonal hematopoiesis, indicating their shared origin. Moreover, molecular karyotype might serve as a strong, inexpensive tool for revealing clonal hematopoiesis in cases of negative targeted next-generation sequencing. Finally, the moderate response of ECD to midostaurin suggests that kinase inhibition might have a potential role in ECD treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. Coexistence of Myeloid and Lymphoid Neoplasms: A Single-Center Experience.
- Author
-
Bouchla, Anthi, Thomopoulos, Thomas, Papageorgiou, Sotirios, Tsirigotis, Panagiotis, Bazani, Efthymia, Gkirkas, Konstantinos, Vasilatou, Diamantina, Glezou, Eirini, Stavroulaki, Georgia, Gkontopoulos, Konstantinos, Dimitriadis, George, and Pappa, Vasiliki
- Subjects
- *
LYMPHOCYTIC leukemia , *TUMORS , *MEDICAL research , *MULTIPLE myeloma , *CHRONIC leukemia , *COMORBIDITY , *WALDENSTROM'S macroglobulinemia - Abstract
The coexistence of a myeloid and a lymphoid neoplasm in the same patient is a rare finding. We retrospectively searched the records of the Hematology Division of the Second Department of Internal Medicine and Research Institute at Attikon University General Hospital of Athens from 2003 to 2018. Nine cases have been identified in a total of 244 BCR-/ABL1- negative MPN and 25 MDS/MPN patients and 1062 LPD patients referred to our institution between 2003 and 2018. Each case is distinct in the diversity of myeloid and lymphoid entities, the chronological occurrence of the two neoplasms, and the patient clinical course. All of them exhibit myeloproliferative (6 JAK2 V617F-positive cases) and lymphoproliferative features, with 1 monoclonal B-cell lymphocytosis (MBL), 3 B-chronic lymphocytic leukemias (B-CLL), 3 B-non-Hodgkin lymphomas (B-NHL), 1 multiple myeloma (MM), and 1 light and heavy deposition disease (LHCDD), while in three cases myelodysplasia is also present. The challenges in identifying and dealing with these rare situations in everyday clinical practice are depicted in this article. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
22. P-192 - Efficacy and safety of methotrexate in the treatment of mycosis fungoides: results from a multicenter study.
- Author
-
Panou, Evdoxia, Tsimpidakis, Antonis, Papadavid, Evangelia, Patsatsi, Aikaterini, Siakantaris, Marina, Kruger-Krasagakis, Sabine, Marinos, Leonidas, Georgiou, Elissavet, Lampadaki, Kyriaki, Velissari, Aliki, Daponte, Αthina-Ioanna, Aikaterini, Doxastaki, Kalliampou, Stela, Vaiopoulos, Aristidiis, Konstandinou, Ilianna, Koumourtzis, Marios, Lakiotaki, Eleftheria, Pappa, Vasiliki, Stratigos, Alaexandros, and Nikolaou, Vasiliki
- Subjects
- *
MYCOSIS fungoides , *CONFERENCES & conventions , *METHOTREXATE , *TREATMENT effectiveness , *PATIENT safety , *PHARMACODYNAMICS - Published
- 2023
- Full Text
- View/download PDF
23. Effectiveness and Safety of Micafungin in Managing Invasive Fungal Infections among Patients in Greece with Hematologic Disorders: The ASPIRE Study.
- Author
-
Kotsopoulou, Maria, Papadaki, Christina, Anargyrou, Konstantinos, Spyridonidis, Alexandros, Baltadakis, Ioannis, Papadaki, Helen A., Angelopoulou, Maria, Pappa, Vasiliki, Liakou, Kleoniki, Tzanetakou, Manto, Moustaka, Marina, and Vassilopoulos, George
- Subjects
- *
MYCOSES , *HEMATOPOIETIC stem cell transplantation , *INVASIVE candidiasis , *CANDIDIASIS , *BLOOD diseases - Abstract
Introduction: Invasive candidiasis (IC) can be a life-threatening infection in immunocompromised patients, particularly those with cancer, hematologic diseases and/or hematopoietic stem cell transplantation (HSCT) recipients. The objective of this study was to evaluate the effectiveness of micafungin in patients with hematologic malignancies or HSCT recipients, relevant to clinical presentation of IC, in real-life practice in Greece. Methods: ASPIRE was a phase IV, multicenter, non-interventional, prospective cohort study, conducted at ten tertiary hospitals in Greece, in adults with hematologic disease. Micafungin treatment for IC or prophylaxis for Candida infection was administered per standard clinical practice until a clinical outcome (success or failure) was reached. Treatment success was defined by the EORTC/MSG criteria for invasive fungal infections (IFI) and was assessed by the investigator. Treatment discontinuation and safety were also evaluated. Results: One hundred forty-three patients were enrolled. Median age was 62; 85 (59.4%) patients were male, and 133 (93.0%) had Greek ethnicity. One hundred twenty-six (88.1%) patients had hematologic malignancies, and 21 (14.7%) had received HSCT. Prophylaxis was administered to 74 (51.7%) patients [median (range) dose: 50 (50–150) mg/day] with no signs of IFI. Overall, 52 (36.4%) patients with possible IFI at baseline received micafungin treatment [100 (50–125) mg/day] versus 12 (17.2%) with probable [100 (75–150) mg/day] and 5 (3.5%) with confirmed [125 (100–150) mg/day] IFI. Treatment success was 91.6% (95% CI 85.80–95.59; n = 131) overall and 90.5% (n = 67) in patients receiving prophylaxis. Median time on treatment was 13 days. Treatment discontinuation (n = 26; 18.2%) was not related to adverse events. No treatment-related serious adverse events were reported. Conclusion: Micafungin treatment for IC or prophylaxis for Candida infection was effective and well tolerated in patients with hematologic disorders in clinical practice in Greece. These results demonstrate that micafungin could be used more widely for prophylaxis. Further work is required to determine the efficacy and safety of micafungin for the management of IFIs in hematologic settings. Funding: Astellas Pharma Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
24. The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5‐azacytidine: Results from the Hellenic 5‐azacytidine registry.
- Author
-
Diamantopoulos, Panagiotis, Koumbi, Dafni, Kotsianidis, Ioannis, Pappa, Vasiliki, Symeonidis, Argiris, Galanopoulos, Athanasios, Zikos, Panagiotis, Papadaki, Helen A., Panayiotidis, Panayiotis, Dimou, Maria, Hatzimichael, Eleftheria, Vassilopoulos, George, Delimpasis, Susan, Mparmparousi, Despoina, Papageorgiou, Sotirios, Variami, Eleni, Kyrtsonis, Marie‐Christine, Megalakaki, Aekaterini, Kotsopoulou, Maria, and Repousis, Panagiotis
- Abstract
In patients with myelodysplastic syndrome (MDS), the prognostic significance of chromosome 17 abnormalities has not yet been fully elucidated, except for isochromosome 17q that has been characterized as an intermediate risk abnormality in the Revised International Prognostic Scoring System (IPSS‐R). To further characterize the prognostic significance of chromosome 17 abnormalities we analyzed the hematologic and prognostic characteristics of 548 adult patients with MDS treated with 5‐azacytidine through the Hellenic 5‐azacytidine registry and found 32 patients with a chromosome 17 abnormality (6 with i[17q], 15 with ‐17, 3 with add[17p] and the rest with other rarer abnormalities, mostly translocations). The presence of a chromosome 17 abnormality was correlated with poor prognostic features (high IPSS, IPSS‐R, and WPSS scores) and a low overall survival rate (15.7 vs 36.4 months for patients without chromosome 17 abnormalities, Kaplan–Meier, Log Rank P < 0.00001), but these results were confounded by the fact that most (92.3%) of the cases with a chromosome 17 abnormality (with the exception of i(17q) that was found in all cases as an isolated abnormality) were found in the context of a complex karyotype. Nevertheless, one should not ignore the contribution of chromosome 17 abnormalities to the prognostic significance of a complex karyotype since 33.8% of complex karyotypes encompassed a chromosome 17 abnormality.To characterize the prognostic significance of chromosome 17 abnormalities we analyzed the hematologic and prognostic characteristics of 548 adult patients with MDS treated with 5‐azacytidine through the Hellenic 5‐azacytidine registry. The presence of a chromosome 17 abnormality (found in 32 patients) was correlated with poor prognostic features and a low overall survival rate. Although these results were confounded by the fact that most cases with a chromosome 17 abnormality were found in the context of a complex karyotype, one should not ignore the contribution of chromosome 17 abnormalities to the prognostic significance of a complex karyotype. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
25. MicroRNA-92a-3p overexpression in peripheral blood mononuclear cells is an independent predictor of prolonged overall survival of patients with chronic lymphocytic leukemia.
- Author
-
Papageorgiou, Sotirios G., Diamantopoulos, Marios A., Kontos, Christos K., Bouchla, Anthi, Vasilatou, Diamantina, Bazani, Efthymia, Scorilas, Andreas, and Pappa, Vasiliki
- Subjects
- *
CHRONIC lymphocytic leukemia , *FLUDARABINE , *BLOOD cells , *BLOOD donors , *TRANSCRIPTION factors - Abstract
MicroRNA-92a-3p (miR-92a-3p) derives from the oncogenic miR-17/92 cluster and its highly homologous miR-106a/363 cluster. miR-92a-3p regulates the expression of key transcription factors such as HIF1 and inhibits SOCS1 to enhance the anti-apoptotic STAT3/IL6 signaling pathway. In this study, we assessed the putative usefulness of miR-92a-3p as a prognostic and/or diagnostic biomarker in chronic lymphocytic leukemia (CLL). For this purpose, total RNA was extracted from mononuclear cells isolated from the peripheral blood of 88 CLL patients and 36 non-leukemic blood donors, was polyadenylated and reversely transcribed. miR-92a-3p expression was quantified using an accurate qPCR method. miR-92a-3p levels were significantly lower in peripheral blood mononuclear cells of CLL patients. Overall survival (OS) analysis revealed that high miR-92a-3p expression predicts significantly prolonged OS of CLL patients. Interestingly, miR-92a-3p overexpression remains a significant prognosticator in subgroups of CLL patients with distinct prognosis. In conclusion, miR-92a-3p overexpression is a potential surrogate biomarker of favorable outcome of CLL patients. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
26. Plasmablastic Lymphoma in an Immunocompetent Patient with MDS/MPN with Ring Sideroblasts and Thrombocytosis—A Case Report.
- Author
-
Bouchla, Anthi, Papageorgiou, Sotirios G., Tsakiraki, Zoi, Glezou, Eirini, Pavlidis, George, Stavroulaki, Georgia, Bazani, Efthimia, Foukas, Periklis, and Pappa, Vasiliki
- Subjects
- *
LYMPHOMAS , *IMMUNOCOMPETENT cells , *MYELODYSPLASTIC syndromes , *CYCLOPHOSPHAMIDE , *BORTEZOMIB - Abstract
Plasmablastic lymphoma (PBL) is a rare, aggressive type of B-cell non-Hodgkin lymphoma with the vast majority of patients responding poorly to treatment or progressing shortly thereafter. Cyclophosphamide-doxorubicin-vincristine-prednisolone (CHOP) or CHOP-like regimens have disappointing results in this setting. We report a case of PBL arising in a previously diagnosed myelodysplastic/myeloproliferative (MDS/MPN) with ring sideroblasts and thrombocytopenia (RS-T), HIV-negative patient treated with the combination of CHOP and bortezomib. The patient achieved complete metabolic response, which has lasted one year, longer by far than would have been expected with the sole use of CHOP. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
27. Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group.
- Author
-
Papageorgiou, Sotirios G., Kotsianidis, Ioannis, Kontos, Christos K., Symeonidis, Argyris, Galanopoulos, Athanasios, Hatzimichael, Eleftheria, Poulakidas, Elias, Diamantopoulos, Panagiotis, Vassilakopoulos, Theodoros P., Zikos, Panagiotis, Papadaki, Helen, Bouronikou, Eleni, Panayiotidis, Panayiotis, Viniou, Nora-Athina, and Pappa, Vasiliki
- Subjects
- *
BODY mass index , *ANTINEOPLASTIC agents , *OVERWEIGHT persons , *MYELOID leukemia , *AZACITIDINE - Published
- 2018
- Full Text
- View/download PDF
28. Elevated miR-20b-5p expression in peripheral blood mononuclear cells: A novel, independent molecular biomarker of favorable prognosis in chronic lymphocytic leukemia.
- Author
-
Papageorgiou, Sotirios G., Kontos, Christos K., Tsiakanikas, Panagiotis, Stavroulaki, Georgia, Bouchla, Anthi, Vasilatou, Diamantina, Bazani, Efthymia, Lazarakou, Afroditi, Scorilas, Andreas, and Pappa, Vasiliki
- Subjects
- *
MICRORNA , *GENE expression , *MONONUCLEAR leukocytes , *BIOMARKERS , *CHRONIC lymphocytic leukemia , *PROGNOSIS - Abstract
MicroRNA-20b-5p (miR-20b-5p) is part of the miR-106a/363 cluster and a member of the cancer-related miR-17 family. miR-20b-5p regulates important transcription factors, including hypoxia-inducible factor 1 (HIF1) and signal transducer and activator of transcription 3 (STAT3). Recently, the dysregulation of miR-20b-5p expression has been observed in many B-cell lymphomas and T-cell leukemias. In this research study, we examined the putative prognostic value of miR-20b-5p in CLL. Therefore, total RNA was isolated from peripheral blood mononuclear cells (PBMCs) collected from 88 CLL patients; next, total RNA was polyadenylated and first-strand cDNA was synthesized, using an oligo-dT–adapter primer. miR-20b-5p expression was quantified using an in-house–developed real-time quantitative PCR assay. Kaplan-Meier OS analysis and bootstrap univariate Cox regression showed that high miR-20b-5p expression predicts better OS for CLL patients ( p < 0.001). Interestingly, miR-20b-5p overexpression retains its favorable prognostic role in CLL patients of intermediate risk or stratified according to established prognostic factors [CD38 expression and mutational status of the immunoglobulin heavy chain variable ( IGHV ) region]. In conclusion, miR-20b-5p is a potential independent molecular biomarker of favorable prognosis in CLL. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
29. MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic Leukemia Patients Is a Novel, Independent Molecular Biomarker of Poor Prognosis.
- Author
-
Papageorgiou, Sotirios G., Kontos, Christos K., Diamantopoulos, Marios A., Bouchla, Anthi, Glezou, Eirini, Bazani, Efthymia, Pappa, Vasiliki, and Scorilas, Andreas
- Subjects
- *
CHRONIC lymphocytic leukemia , *MICRORNA , *GENETIC overexpression , *GENETIC markers , *MONONUCLEAR leukocytes , *BLOOD cells , *PROGNOSIS - Abstract
MicroRNA-155-5p (miR-155-5p) is a proinflammatory, oncogenic miRNA, involved in various physiological processes, including hematopoiesis, immunity, inflammation, and cell lineage differentiation. It regulates important transcription factors, such as E2F2, hypoxia-inducible factor 1 (HIF1), and FOXO3. Recently, the dysregulation of miR-155-5p expression has been linked to chronic lymphocytic leukemia (CLL) pathogenesis. In this research study, we investigated the potential diagnostic and prognostic value of miR-155-5p in CLL. To achieve our goal, we isolated total RNA from peripheral blood mononuclear cells (PBMCs) collected from 88 CLL patients and 36 nonleukemic blood donors and performed polyadenylation of total RNA and reverse transcription. Next, we quantified miR-155-5p levels using an in-house-developed real-time quantitative PCR method, before proceeding to extensive biostatistical analysis. Thus, it appears that miR-155-5p is significantly overexpressed in PBMCs of CLL patients and can distinguish them from nonleukemic population. Kaplan-Meier OS analysis and bootstrap univariate Cox regression showed that high miR-155-5p expression predicts inferior OS for CLL patients (p<0.001). Interestingly, miR-155-5p overexpression retains its unfavorable prognostic role in CLL patients stratified according to established prognostic factors [CD38 expression and mutational status of the immunoglobulin heavy chain variable region (IGHV)]. Thus, miR-155-5p appears as a promising, independent molecular biomarker of unfavorable prognosis in CLL. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
30. Quantitative and qualitative analysis of regulatory T cells in B cell chronic lymphocytic leukemia.
- Author
-
Mpakou, Vassiliki E., Ioannidou, Heleni-Dikaia, Konsta, Eugene, Vikentiou, Myrofora, Spathis, Aris, Kontsioti, Frieda, Kontos, Christos K., Velentzas, Athanassios D., Papageorgiou, Sotiris, Vasilatou, Diamantina, Gkontopoulos, Konstantinos, Glezou, Irene, Stavroulaki, Georgia, Mpazani, Efthimia, Kokkori, Stella, Kyriakou, Elias, Karakitsos, Petros, Dimitriadis, George, and Pappa, Vasiliki
- Subjects
- *
T cells , *PATHOGENIC microorganisms , *CHRONIC lymphocytic leukemia , *CARCINOGENESIS , *IMMUNOPHENOTYPING - Abstract
Accumulated data indicate a significant role of T cell dysfunction in the pathogenesis of chronic lymphocytic leukemia. In CLL, regulatory T cells are significantly higher and show lower apoptotic levels compared to healthy donors. We demonstrate that CLL derived CD4 + CD25 − CD127 − and CD4 + CD25 low CD127 − subpopulations share a common immunophenotypic profile with conventional Tregs and are associated with advanced stage disease. We further provide evidence that the increased number of Tregs contributes indirectly to the proliferation of the CLL clone, by suppressing the proliferation of Teffs which in turn suppress CLL cells. These data are further supported by our observations that CLL derived Tregs appear rather incapable of inducing apoptosis of both normal B cells and CLL cells, in contrast to normal Tregs, suggesting an immunoediting effect of CLL cells on Tregs which negatively affects the functionality of the latter and contributes to the failure of Tregs in CLL to efficiently eliminate the abnormal clone. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
31. mRNA overexpression of the hypoxia inducible factor 1 alpha subunit gene (HIF1A): An independent predictor of poor overall survival in chronic lymphocytic leukemia.
- Author
-
Kontos, Christos K., Papageorgiou, Sotirios G., Diamantopoulos, Marios A., Scorilas, Andreas, Bazani, Efthimia, Vasilatou, Diamantina, Gkontopoulos, Konstantinos, Glezou, Eirini, Stavroulaki, Georgia, Dimitriadis, George, and Pappa, Vasiliki
- Subjects
- *
LYMPHOBLASTIC leukemia diagnosis , *HYPOXIA-inducible factor 1 , *GENE expression , *POLYMERASE chain reaction , *BIOMARKERS - Abstract
The hypoxia inducible factor 1 (HIF1) is a heterodimeric transcription factor that ultimately regulates cellular responses to changes in oxygen tension. In this study, we examined the potential diagnostic and prognostic potential of the mRNA expression of HIF1 regulatory α-subunit ( HIF1A ) in chronic lymphocytic leukemia (CLL). For this purpose, total RNA was isolated from peripheral blood mononuclear cells collected from 88 CLL patients and 33 non-leukemic blood donors, and poly(A)-RNA was reversely transcribed. HIF1A mRNA levels were quantified using real-time PCR. Kaplan-Meier survival analysis showed that high HIF1A mRNA expression predicts inferior overall survival for CLL patients ( p = 0.001). Bootstrap univariate Cox regression analysis confirmed that HIF1A mRNA overexpression is a significant unfavorable prognosticator in CLL (hazard ratio = 3.75, bias-corrected and accelerated 95% confidence interval = 1.43–24.36, bootstrap p < 0.001), independent of other established prognostic factors, including CD38 expression, the mutational status of the immunoglobulin heavy chain variable region ( IGHV ), and the clinical stage (Binet or Rai stage) or risk group ( p < 0.001 in all cases). Interestingly, HIF1A mRNA positivity retains its unfavorable prognostic value in distinct subgroups of patients, stratified according to established prognostic factors. Thus, HIF1A mRNA overexpression can be regarded as a promising, independent molecular biomarker of unfavorable prognosis in CLL. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
32. Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and Methotrexate.
- Author
-
Mpakou, Vassiliki, Papadavid, Evangelia, Kontsioti, Frieda, Konsta, Eugene, Vikentiou, Miriam, Spathis, Aris, Papageorgiou, Sotiris, Vasilatou, Diamantina, Gkontopoulos, Konstantinos, Mpazani, Efthimia, Karakitsos, Petros, Rigopoulos, Dimitrios, Dimitriadis, George, and Pappa, Vasiliki
- Subjects
- *
APOPTOSIS , *GENE expression , *T-cell lymphoma , *BORTEZOMIB , *METHOTREXATE , *CANCER cells , *THERAPEUTICS - Abstract
Mycosis fungoides (MF) and its leukemic variant Sézary syndrome (SS) comprise the majority of CTCL, a heterogenous group of non-Hodgkins lymphomas involving the skin. The CTCL’s resistance to chemotherapy and the lack of full understanding of their pathogenesis request further investigation. With the view of a more targeted therapy, we evaluated in vitro the effectiveness of bortezomib and methotrexate, as well as their combination in CTCL cell lines, regarding apoptosis induction. Our data are of clinical value and indicate that the bortezomib/methotrexate combinational therapy has an inferior impact on the apoptosis of CTCL compared to monotherapy, with bortezomib presenting as the most efficient treatment option for SS and methotrexate for MF. Using PCR arrays technology, we also investigated the alterations in the expression profile of genes related to DNA repair pathways in CTCL cell lines after treatment with bortezomib or methotrexate. We found that both agents, but mostly bortezomib, significantly deregulate a large number of genes in SS and MF cell lines, suggesting another pathway through which these agents could induce apoptosis in CTCL. Finally, we show that SS and MF respond differently to treatment, verifying their distinct nature and further emphasizing the need for discrete treatment approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
33. Epstein barr virus hemophagocytic lymphohistiocytosis related to rituximab use and immunopathogenetic insights.
- Author
-
Papageorgiou, Sotirios G., Tsiodras, Sotirios, Siakallis, Georgios, Bazani, Efthimia, Spathis, Aris, Poulakou, Garyfalia, Korkolopoulou, Penelope, Panayiotides, Ioannis, and Pappa, Vasiliki
- Subjects
- *
EPSTEIN-Barr virus , *RITUXIMAB , *HODGKIN'S disease , *CANCER chemotherapy , *LYMPHOPROLIFERATIVE disorders , *RICHTER syndrome , *CHRONIC lymphocytic leukemia - Abstract
Anti-CD20-based chemo-immunotherapeutic regimens have been suggested to assist in the management of Epstein-Barr virus (EBV)-induced hemophagocytic lymphohistiocytosis (HLH) and EBV-associated post-transplant lymphoproliferative disorders (EBV-PTLD), by reducing EBV viral load and EBV-induced inflammation. Herein we report a fatal EBV-related HLH in the context of Hodgkin lymphoma (HL)-like Richter’s transformation of B chronic lymphocytic leukemia (B-CLL), two months after rituximab treatment. The complex balance between EBV driven T-cell stimulation and immunosuppressive therapy in the context of multiple immune deficits is discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
34. BCL2L12 protein overexpression is associated with favorable outcome in diffuse large B-cell lymphoma patients in the rituximab era.
- Author
-
Papageorgiou, Sotirios G., Kontos, Christos K., Foukas, Periklis G., Panopoulou, Eleni, Vasilatou, Diamantina, Rapti, Stamatia-Maria, Gkontopoulos, Konstantinos, Bazani, Efthimia, Panayiotides, Ioannis G., Dimitriadis, George, Scorilas, Andreas, and Pappa, Vasiliki
- Subjects
- *
DIFFUSE large B-cell lymphomas , *BCL-2 proteins , *PROTEIN overexpression , *RITUXIMAB , *GENETIC overexpression , *CYCLOPHOSPHAMIDE , *DOXORUBICIN , *VINCRISTINE , *CANCER chemotherapy , *GENETICS - Abstract
The article discusses the overexpression of BCL2L12 protein associated with favorable outcome in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab. The study included formalin-fixed paraffin-embedded tissue biopsies from newly diagnosed DLBCL patients, and other conventional chemotherapy treatments like cyclophosphamide, doxorubicin, and vincristine. Assessments performed include immunohistochemistry, RNA isolation from cultured cells, and multivariate Cox regression.
- Published
- 2016
- Full Text
- View/download PDF
35. Soluble factors influencing the neural stem cell niche in brain physiology, inflammation, and aging.
- Author
-
Willis, Cory M., Nicaise, Alexandra M., Krzak, Grzegorz, Ionescu, Rosana-Bristena, Pappa, Vasiliki, D'Angelo, Andrea, Agarwal, Ravi, Repollés-de-Dalmau, Maria, Peruzzotti-Jametti, Luca, and Pluchino, Stefano
- Subjects
- *
STEM cell niches , *NEURAL stem cells , *BRAIN physiology , *CENTRAL nervous system , *CELL physiology - Abstract
Within the adult central nervous system (CNS) of most mammals resides a resident stem cell population, known as neural stem cells (NSCs). NSCs are located within specific niches of the CNS and maintain a self-renewal and proliferative capacity to generate new neurons, astrocytes, and oligodendrocytes throughout adulthood. The NSC niches are dynamic and active environments that are within proximity to the systemic circulation and the cerebrospinal fluid (CSF). Therefore, NSCs respond not only to factors present in the local microenvironment of the niche but also to factors present in the systemic macroenvironment. The factors can be soluble forms such as cytokines and chemokines located in the circulation or directly from local cells, such as microglia and astrocytes. Additionally, recent evidence points towards physiological aging and its association with a progressive loss of function and a decline in the self-renewal and regenerative capacities of CNS NSCs, which can be further exacerbated by changes in the local and systemic milieu. This review will highlight the main intrinsic and extrinsic regulators of neural stem cell function under homeostatic and inflammatory conditions including those trafficked within extracellular membrane vesicles. Further, discussion will center around how intrinsic and extrinsic factors impact normal homeostatic functions within the adult brain and in aging. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
36. Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the 'real life' setting: A single center observational study.
- Author
-
Papageorgiou, Sotirios G., Vasilatou, Diamantina, Kontos, Christos K., Foukas, Periklis, Kefala, Maria, Ioannidou, Eleni-Dikaia, Bouchla, Anthi, Bazani, Efthymia, Dimitriadis, George, and Pappa, Vasiliki
- Subjects
- *
AZACITIDINE , *MYELODYSPLASTIC syndromes , *SCIENTIFIC observation , *RETROSPECTIVE studies , *DISEASE progression , *HEALTH outcome assessment , *PATIENTS , *PROGNOSIS , *DISEASE risk factors , *THERAPEUTICS - Abstract
Objectives: The demethylating factor 5-Azacytidine (5-AZA) improves survival of patients with myelodysplastic syndromes (MDS) in randomized control trials but the results in 'real life' are controversial. Methods: In this retrospective study, we evaluated the outcome of 56 high-risk MDS patients who were treated with 5-AZA between 2005 and 2013. 5-AZA was administered in an outpatient basis at a dose 75 mg/m2 s.c. with the following schedule: 5 days on/weekend off/2 days on (5/2/2). Results: The overall response rate (ORR) was 50%; 21.2% patients achieved complete response (CR), 3.8% partial response (PR), and 25% hematologic improvement (HI); 34.6% had stable disease (SD) and 15.4% showed progressive disease (PD). The estimated median event free survival (EFS) and overall survival (OS) were 11 and 17 months, respectively. Interestingly, the estimated time to acute myeloid leukemia transformation was 30 months, which refers to patients who responded to AZA treatment or remained stable. Patients who responded to the 5-AZA achieving CR, PR, and HI had better EFS and OS compared to the patients who had SD or PD. In addition, Δ WHO Classification-based Prognostic Score System (ΔWPSS), which represents the improvement of WPSS risk group before and after treatment, was associated with significantly improved OS and better EFS. Finally, the response to treatment was not associated with the expression of p53. Conclusions: In conclusion, 5-AZA is an effective treatment for high-risk MDS. Improved OS and EFS were found mainly in patients who responded to the treatment while ΔWPSS seems to represent a promising future prognostic tool. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
37. Combination of Resminostat with Ruxolitinib Exerts Antitumor Effects in the Chick Embryo Chorioallantoic Membrane Model for Cutaneous T Cell Lymphoma.
- Author
-
Karagianni, Fani, Piperi, Christina, Casar, Berta, de la Fuente-Vivas, Dalia, García-Gómez, Rocío, Lampadaki, Kyriaki, Pappa, Vasiliki, and Papadavid, Evangelia
- Subjects
- *
BIOLOGICAL models , *EMBRYOS , *POULTRY , *ANIMAL experimentation , *ANTINEOPLASTIC agents , *FETAL membranes , *APOPTOSIS , *METASTASIS , *JANUS kinases , *CELL proliferation , *NEUROTRANSMITTER uptake inhibitors , *HISTONE deacetylase , *CELL lines , *CUTANEOUS T-cell lymphoma , *PHARMACODYNAMICS , *CHEMICAL inhibitors - Abstract
Simple Summary: The combination of Resminostat (HDACi) and Ruxolitinib (JAKi) exerted cytotoxic effects and inhibited proliferation of CTCL cell lines (MyLa, SeAx) in vitro. The aim of the present study was to validate their antitumor effects in vivo using the chick embryo chorioallantoic membrane (CAM) model, which allows quick and efficient monitoring of tumor growth, migration, invasion, and metastatic potential. The drug combination exhibited a significant inhibition of primary tumor size, and inhibited intravasation and extravasation of tumor cells to the liver and lung. It also exerted an inhibitory effect in the migration and invasion of tumor cells and significantly reduced key signaling pathway activation. Our data demonstrate that the CAM assay could be employed as a preclinical in vivo model in CTCL for pharmacological testing, and that the combination of Resminostat and Ruxolitinib exerts significant antitumor effects in CTCL progression that need to be further evaluated in a clinical setting. The combination of Resminostat (HDACi) and Ruxolitinib (JAKi) exerted cytotoxic effects and inhibited proliferation of CTCL cell lines (MyLa, SeAx) in previously published work. A xenograft tumor formation was produced by implanting the MyLa or SeAx cells on top of the chick embryo chorioallantoic membrane (CAM). The CAM assay protocol was developed to monitor the metastatic properties of CTCL cells and the effects of Resminostat and/or Ruxolitinib in vivo. In the spontaneous CAM assays, Resminostat and Ruxolitinib treatment inhibited the cell proliferation (p < 0.001) of MyLa and SeAx, and induced cell apoptosis (p < 0.005, p < 0.001, respectively). Although monotherapies reduced the size of primary tumors in the metastasis CAM assay, the drug combination exhibited a significant inhibition of primary tumor size (p < 0.0001). Furthermore, the combined treatment inhibited the intravasation of MyLa (p < 0.005) and SeAx cells (p < 0.0001) in the organs, as well as their extravasation to the liver (p < 0.0001) and lung (p < 0.0001). The drug combination also exerted a stronger inhibitory effect in migration (p < 0.0001) rather in invasion (p < 0.005) of both MyLa and SeAx cells. It further reduced p-p38, p-ERK, p-AKT, and p-STAT in MyLa cells, while it decreased p-ERK and p-STAT in SeAx cells in CAM tumors. Our data demonstrated that the CAM assay could be employed as a preclinical in vivo model in CTCL for pharmacological testing. In agreement with previous in vitro data, the combination of Resminostat and Ruxolitinib was shown to exert antitumor effects in CTCL in vivo. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
38. CNS Involvement in AML Patient Treated with 5-Azacytidine.
- Author
-
Vasilatou, Diamantina, Papageorgiou, Sotirios, Bazani, Efthymia, Prasouli, Athina, Economopoulou, Christina, Roumpakis, Christoforos, Karakitsos, Petros, Dimitriadis, George, and Pappa, Vasiliki
- Subjects
- *
CENTRAL nervous system diseases , *ACUTE myeloid leukemia treatment , *AZACITIDINE , *BLOOD cell count , *CANCER chemotherapy , *MAGNETIC resonance imaging - Abstract
Central nervous system (CNS) involvement in acute myeloid leukemia (AML) is a rare complication of the disease and is associated with poor prognosis. Sometimes the clinical presentation can be unspecific and the diagnosis can be very challenging. Here we report a case of CNS infiltration in a patient suffering from AML who presented with normal complete blood count and altered mental status. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
39. Increased expression of phosphorylated NBS1, a key molecule of the DNA damage response machinery, is an adverse prognostic factor in patients with de novo myelodysplastic syndromes.
- Author
-
Kefala, Maria, Papageorgiou, Sotirios G., Kontos, Christos K., Economopoulou, Panagiota, Tsanas, Athanasios, Pappa, Vasiliki, Panayiotides, Ioannis G., Gorgoulis, Vassilios G., Patsouris, Eustratios, and Foukas, Periklis G.
- Subjects
- *
PHOSPHORYLATION , *GENE expression , *DNA repair , *MYELODYSPLASTIC syndromes , *IMMUNOHISTOCHEMISTRY , *BONE marrow , *BIOPSY , *PROGNOSIS - Abstract
Abstract: The expression of activated forms of key proteins of the DNA damage response machinery (pNBS1, pATM and γH2AX) was assessed by means of immunohistochemistry in bone marrow biopsies of 74 patients with de novo myelodysplastic syndromes (MDS) and compared with 15 cases of de novo acute myeloid leukemia (AML) and 20 with reactive bone marrow histology. Expression levels were significantly increased in both MDS and AML, compared to controls, being higher in high-risk than in low-risk MDS. Increased pNBS1 and γH2AX expression possessed a significant negative prognostic impact for overall survival in MDS patients, whereas pNBS1 was an independent marker of poor prognosis. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
40. Epigenetic alterations and microRNAs.
- Author
-
Vasilatou, Diamantina, Papageorgiou, Sotirios G., Dimitriadis, George, and Pappa, Vasiliki
- Published
- 2013
- Full Text
- View/download PDF
41. Expression analysis of mir-17-5p, mir-20a and let-7a microRNAs and their target proteins in CD34+ bone marrow cells of patients with myelodysplastic syndromes
- Author
-
Vasilatou, Diamantina, Papageorgiou, Sotirios G., Kontsioti, Frieda, Kontos, Christos K., Tsiotra, Panayiota, Mpakou, Vassiliki, Pavlou, Maria-Angeliki S., Economopoulou, Christina, Dimitriadis, George, Dervenoulas, John, and Pappa, Vasiliki
- Subjects
- *
GENE expression , *MICRORNA , *GENE targeting , *CD34 antigen , *BONE marrow cells , *MYELODYSPLASTIC syndromes , *GENETIC regulation , *PATIENTS - Abstract
Abstract: Mir-17-5p and mir-20a, members of the mir-17-92 family, down-regulate E2F1, which is over-expressed in myelodysplastic syndromes (MDS). Moreover, let-7a down-regulates KRAS, which is aberrantly expressed in MDS. We evaluated the expression of the aforementioned microRNAs in CD34+ cells of 43 MDS patients using real-time PCR and their target proteins (E2F1, MYC, BCL2, CCND1, and KRAS) by Western blot. Mir-17-5p and mir-20a were under expressed in high risk MDS patients, compared to low risk MDS patients. Similarly, let-7a was under expressed in patients with intermediate or high-risk karyotype. Interestingly, there was an inverse correlation between microRNA and the expression levels of their targets. Importantly, mir-17-5p and mir-20a constitute favorable prognostic factors in MDS, since their expression was associated with increased overall survival of MDS patients. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
42. Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation
- Author
-
Mpakou, Vassiliki E., Kontsioti, Frieda, Papageorgiou, Sotiris, Spathis, Aris, Kottaridi, Christine, Girkas, Kostas, Karakitsos, Petros, Dimitriadis, George, Dervenoulas, Ioannis, and Pappa, Vasiliki
- Subjects
- *
ACUTE myeloid leukemia , *IMATINIB , *CELL proliferation , *APOPTOSIS , *PROTEIN-tyrosine kinases , *CELL lines , *GENETIC mutation , *CLINICAL trials , *PHOSPHORYLATION - Abstract
Abstract: Activating mutations of the c-kit gene are frequently found in CBF (core binding factor) leukemias. We evaluated the effect of tyrosine kinase inhibitor dasatinib in leukemic cell lines bearing or not c-kit mutations. Our data demonstrate that in the AML Kasumi-1 cell line, bearing the N822K c-kit mutation, dasatinib is a potent suppressor of c-kit and Src kinase activity and inhibits the phosphorylation of their downstream target AKT, possibly through the Src-mediated VEGF/VEGFR receptor type 2 pathway. Dasatinib also effectively blocks proliferation and induces apoptosis through caspase-3 activation in Kasumi-1 cells. These data further encourage the integration of dasatinib in the treatment of CBF AML with c-kit mutations in the context of clinical trials, which are eagerly anticipated. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
43. Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The hellenic experience
- Author
-
Siakantaris, Marina P., Tsirigotis, Panagiotis, Stavroyianni, Niki, Argyropoulos, Kimon V., Girkas, Konstantinos, Pappa, Vasiliki, Chondropoulos, Spiros, Papadavid, Evangelia, Sakellari, Ioanna, Anagnostopoulos, Achilles, Antoniou, Christina, and Dervenoulas, John
- Subjects
- *
T-cell lymphoma , *PHOTOCHEMOTHERAPY , *DRUG efficacy , *IMMUNOREGULATION , *PALLIATIVE treatment , *TREATMENT effectiveness , *FOLLOW-up studies (Medicine) - Abstract
Abstract: Extracorporeal photopheresis (ECP) is an established therapy for cutaneous T-cell lymphoma (CTCL). The objective of this study was to further explore the clinical efficacy of ECP combined with immunomodulatory agents. Eighteen patients with histologically proven CTCL were followed-up after therapy with ECP, mainly combined with interferon-α or bexarotene. A total of 61% of patients responded to therapy (n =11; CR: 5, PR: 6). Median survival was 51months, progression free survival was 28months and response duration was 29±23.9months. ECP combined therapy was highly effective or had a palliative effect in CTCL resistant to previous treatments. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
44. Acute myelogenous leukemia with tetrasomy 8 is a disease with a poor prognosis
- Author
-
Tsirigotis, Panagiotis, Papageorgiou, Sotirios, Abatzis, Danai, Athanatou, Sofia, Girkas, Constantinos, Pappa, Vasiliki, Pangalos, Constantinos, Papageorgiou, Efstathios, Dervenoulas, John, and Raptis, Sotirios
- Subjects
- *
ACUTE myeloid leukemia , *PROGNOSIS , *PATIENTS , *CHROMOSOMES - Abstract
Abstract: Tetrasomy 8 is an extremely rare chromosome abnormality, one that has been reported in only a few cases with myeloid malignancies. The majority of reported cases consist of acute myelogenous leukemias (AML) of monocytic lineage. In slightly more than half of the patients, tetrasomy 8 was the single cytogenetic abnormality. Fluorescence in situ hybridization revealed tetrasomy 8 and trisomy 8 concurrently in all but one of the bone marrow samples. The clonal relationship between trisomy 8 and tetrasomy 8 in these cases remains to be clarified. Patients with tetrasomy 8 have a poor prognosis, and only 1 out of 33 patients was free of disease 3 years after autologous bone marrow transplantation. Here, we report the case of a 25-year-old female patient with monocytic leukemia and tetrasomy 8. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
45. Solitary extramedullary plasmacytoma of the nasopharynx: The role of flow cytometry.
- Author
-
Loucari, Constantinos C., Foukas, Periklis G., Spathis, Aris, Tsakiraki, Zoi, Apostolopoulou, Christina, Thomopoulos, Thomas, Bouchla, Anthi, Oikonomopoulos, Nikolaos, Maragkoudakis, Pavlos, Pappa, Vasiliki, and Papageorgiou, Sotirios G.
- Subjects
- *
PLASMACYTOMA , *EXTRAMEDULLARY diseases , *FLOW cytometry , *MUCOSA-associated lymphoid tissue lymphoma , *NASOPHARYNX , *PLASMA cells , *IMMUNOHISTOCHEMISTRY - Abstract
Extramedullary plasmacytoma (EMP) represents a distinct yet rare entity among the plasma cell neoplasms. Given its rarity, no therapeutic consensus has been met. We report the case of a 57-year-old man with a one-year history of nasal congestion and occasional dyspnoea. Imaging showed a hypermetabolic mass in the right nasopharynx extending backward towards the adjacent oropharynx, infiltrating the epiglottis. As incisional biopsy showed histologic and immunophenotypic features consistent with plasma cell neoplasm, whereas the possibility of a marginal zone lymphoma with plasmacytic differentiation was included in the differential diagnosis. A final diagnosis of EMP was reached by using flow cytometry (FC) of a cell suspension from the neoplastic tissue. The patient received local radiotherapy (RT) which resulted to complete remission. In conclusion, flow cytometry might serve as an auxiliary method in cases where immunohistochemistry cannot differentiate between a plasma cell dyscrasia and a B-non-Hodgkin lymphoma. In cases of an established diagnosis of solitary nasopharyngeal EMP RT represents an excellent treatment modality offering prolonged disease-free survival. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
46. Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study.
- Author
-
Terpos, Evangelos, Repousis, Panagiotis, Lalayanni, Chrysavgi, Hatjiharissi, Evdoxia, Assimakopoulou, Theodora, Vassilopoulos, Georgios, Pouli, Anastasia, Spanoudakis, Emmanouil, Michalis, Eurydiki, Pangalis, Gerassimos, Ntanasis-Stathopoulos, Ioannis, Poziopoulos, Christos, Kyrtsonis, Marie-Christine, Pappa, Vasiliki, Symeonidis, Argiris, Georgopoulos, Christos, Zikos, Panagiotis M., Gavriatopoulou, Maria, Papadaki, Helen A., and Dadakaridou, Magdalini
- Subjects
- *
MULTIPLE myeloma , *DEXAMETHASONE , *PROGRESSION-free survival , *ACQUISITION of data - Abstract
The "POWERFUL" multicenter, retrospective, and prospective study investigated the effectiveness of pomalidomide plus low-dose dexamethasone (POM/LoDex) therapy in relapsed/refractory multiple myeloma in routine care in Greece. Ninety-nine eligible adult patients treated with POM/LoDex according to the approved label after having received ≥2 prior therapies, including lenalidomide and bortezomib, were consecutively enrolled between 16 November 2017 and 21 February 2019 in 18 hematology departments. Fifty patients (50.5%) started POM/LoDex as third-line treatment. During the treatment period (median: 8.3 months; range: 0.3–47.6 months), the median POM dose was 4 mg/day, and 31.3% of the patients received additional antimyeloma agents. The overall response rate was 32.3%. During a median follow-up period of 13.8 months (Kaplan–Meier estimate), the median progression-free survival (PFS) was 10.5 months (95% CI: 7.4–14.4). The PFS was not significantly different between patients receiving POM/LoDex in the third versus later line of therapy, nor between patients receiving concomitant antimyeloma therapy versus POM/LoDEx doublet. During the prospective safety data collection period (median: 7.6 months) among patients with prospective follow-up (N = 75), POM-related adverse event incidence rate was 42.7% (serious: 18.7%; grade ≥ 3 hematological POM-related adverse events: 8.0%). Only neutropenia (13.3%) was reported at a frequency ≥10%. In conclusion, in this real-world study, POM/LoDex displayed a long PFS with no new safety signals emerging. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
47. Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1.
- Author
-
Mpakou, Vassiliki, Spathis, Aris, Bouhla, Anthi, Mpazani, Efthimia, Papageorgiou, Sotirios, Gkontopoulos, Konstantinos, Glezou, Eirini, Thomopoulos, Thomas, Foukas, Periklis, and Pappa, Vasiliki
- Subjects
- *
DECITABINE , *ACUTE myeloid leukemia , *BORTEZOMIB , *CELL lines , *DNA synthesis , *DNA methyltransferases - Abstract
In the present study, the ability of the proteasome inhibitor bortezomib (BZ), an oxidative stress-inducing agent, to sensitize acute myeloid leukemia (AML) cells to decitabine (Dacogen®, DAC; a DNA methyltransferase inhibitor), in terms of cell viability and differentiation, was investigated. Kasumi-1 AML (M2) cells were treated with low-dose DAC (10, 50, 100, 200 or 400 nΜ), with or without BZ (10 nM). Apoptosis and the cell cycle were evaluated after 24 h of treatment through fluorescence-assisted cell sorting (FACS) with Annexin V/propidium iodide and DAPI staining, respectively. The expression levels of CD193, CD11b, CD13, CD14, CD15, CD16 and CD117 surface differentiation markers were evaluated by FACS after 6 days of treatment. The results indicated significant alterations in cell death and cell cycle phases in Kasumi-1 cells following DAC and BZ combination treatment compared to untreated cells and cells with single treatments. Low-dose DAC/BZ combinations significantly enhanced apoptosis and decreased the population of live Kasumi-1 cells, with 100 and 200 nM of DAC and 10 nM BZ appearing to have the most potent synergistic effect according to a combination index. Furthermore, cell cycle profiling revealed that DAC/BZ treatment synergistically led to G0/G1- and G2/M-phase arrest. By contrast, DAC appeared to promote monocytic and granulocytic differentiation of Kasumi-1 cells more effectively alone than in combination with BZ. BZ acted synergistically with low-dose DAC in vitro, leading to enhanced apoptosis and G0/G1- and G2/M-phase arrest in AML cells, hence prohibiting either DNA synthesis or mitosis. Although further in vivo investigation is necessary, these results provide a strong rationale for the implementation of a combination treatment with DAC and bortezomib in AML therapy, followed by DAC alone, which may achieve better clinical responses and possibly partially overcome the frequently encountered DAC resistance of patients with AML. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
48. MicroRNAs: Tiny Regulators of Gene Expression with Pivotal Roles in Normal B-Cell Development and B-Cell Chronic Lymphocytic Leukemia.
- Author
-
Katsaraki, Katerina, Karousi, Paraskevi, Artemaki, Pinelopi I., Scorilas, Andreas, Pappa, Vasiliki, Kontos, Christos K., Papageorgiou, Sotirios G., and Tucci, Paola
- Subjects
- *
CHRONIC lymphocytic leukemia diagnosis , *THERAPEUTIC use of antineoplastic agents , *CHRONIC lymphocytic leukemia , *DISEASE progression , *B cells , *MICRORNA , *GENE expression , *TUMOR markers , *TRANSCRIPTION factors , *HEMATOPOIESIS , *PREDICTION models - Abstract
Simple Summary: The involvement of miRNAs in physiological cellular processes has been well documented. The development of B cells, which is dictated by a miRNA-transcription factor regulatory network, suggests a typical process partly orchestrated by miRNAs. Besides their contribution in normal hematopoiesis, miRNAs have been severally reported to be implicated in hematological malignancies, a typical example of which is B-cell chronic lymphocytic leukemia (B-CLL). Numerous studies have attempted to highlight the regulatory role of miRNAs in B-CLL or establish some of them as molecular biomarkers or therapeutic targets. Thus, a critical review summarizing the current knowledge concerning the multifaceted role of miRNAs in normal B-cell development and B-CLL progression, prognosis, and therapy, is urgent. Moreover, this review aims to highlight important miRNAs in both normal B-cell development and B-CLL and discuss future perspectives concerning their regulatory potential and establishment in clinical practice. MicroRNAs (miRNAs) represent a class of small non-coding RNAs bearing regulatory potency. The implication of miRNAs in physiological cellular processes has been well documented so far. A typical process orchestrated by miRNAs is the normal B-cell development. A stage-specific expression pattern of miRNAs has been reported in the developmental procedure, as well as interactions with transcription factors that dictate B-cell development. Besides their involvement in normal hematopoiesis, miRNAs are severally implicated in hematological malignancies, a typical paradigm of which is B-cell chronic lymphocytic leukemia (B-CLL). B-CLL is a highly heterogeneous disease characterized by the accumulation of abnormal B cells in blood, bone marrow, lymph nodes, and spleen. Therefore, timely, specific, and sensitive assessment of the malignancy is vital. Several studies have attempted to highlight the remarkable significance of miRNAs as regulators of gene expression, biomarkers for diagnosis, prognosis, progression, and therapy response prediction, as well as molecules with potential therapeutic utility. This review seeks to outline the linkage between miRNA function in normal and malignant hematopoiesis by demonstrating the main benchmarks of the implication of miRNAs in the regulation of normal B-cell development, and to summarize the key findings about their value as regulators, biomarkers, or therapeutic targets in B-CLL. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
49. Rosuvastatin-Induced Thrombocytopenia.
- Author
-
Vrettos, loannis, Papageorgiou, Sotiris, Economopoulou, Christina, Pappa, Vasiliki, Tsirigotis, Panagiotis, Tountas, Nikolaos, Economopoulos, Theofanis, and Dervenoulas, John
- Subjects
- *
WOMEN'S health , *STATINS (Cardiovascular agents) , *VITILIGO , *BLOOD platelets , *THROMBOCYTOPENIA - Abstract
The article presents a case report of a 65-year-old woman who was taken to a hematology section with a platelet count of 31 x 103/ μL. Her medical history included dyslipidemia, vitiligo and appendicectomy. It says that her rosuvastatin medication was stopped and her platelet rose to 15 x 103/ μL after six months, suggesting that she suffered rosuvastatin-induced thrombocytopenia. Moreover, the link between statin and thrombocytopenia is explored.
- Published
- 2010
- Full Text
- View/download PDF
50. Identification of a novel, internal tRNA-derived RNA fragment as a new prognostic and screening biomarker in chronic lymphocytic leukemia, using an innovative quantitative real-time PCR assay.
- Author
-
Katsaraki, Katerina, Artemaki, Pinelopi I., Papageorgiou, Sotirios G., Pappa, Vasiliki, Scorilas, Andreas, and Kontos, Christos K.
- Subjects
- *
CHRONIC lymphocytic leukemia , *RNA , *NON-coding RNA - Abstract
• An innovative qPCR method for quantification of i-tRF-GlyCCC levels was developed. • High i-tRF-GlyCCC expression predicts poor overall survival in CLL patients. • Prognostic significance of i-tRF-GlyCCC is independent of other prognostic factors. • i-tRF-GlyCCC is an unfavorable prognosticator in distinct subgroups of CLL patients Chronic lymphocytic leukemia (CLL) is one of the most common types of leukemia in adults. Several studies have identified various prognostic biomarkers in CLL. In this study, we investigated the potential value of an internal fragment of the tRNAs bearing the Glycine anticodon CCC (i-tRF-GlyCCC), which is a small non-coding RNA, as a prognostic and screening biomarker in CLL. For this purpose, blood samples were collected from 90 CLL patients and 43 non-leukemic blood donors. Peripheral blood mononuclear cells (PBMCs) were isolated, total RNA was extracted and in-vitro polyadenylated, and first-strand cDNA was synthesized using an oligo-dT–adaptor primer. A real-time quantitative PCR assay was developed and applied for the quantification of i-tRF-GlyCCC in our samples. The biostatistical analysis revealed that i-tRF-GlyCCC levels are significantly lower in PBMCs of CLL patients, compared to PBMCs of non-leukemic controls, and that i-tRF-GlyCCC could be considered as a screening biomarker. Kaplan-Meier overall survival (OS) analysis revealed reduced OS for CLL patients with positive i-tRF-GlyCCC expression (P = 0.001). Multivariate Cox regression confirmed its independent unfavorable prognostic power with regard to OS. In conclusion, i-tRF-GlyCCC may constitute a promising molecular biomarker in CLL, for screening and prognostic purposes. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.